膝神经射频消融与关节腔内注射的并发症及阿片类药物处方模式:匹配队列研究
本研究利用大型国家数据库,匹配比较膝神经射频消融(GNRFA)与关节腔内皮质类固醇注射(CSI)或透明质酸注射(HAI)患者的30天和90天并发症率及治疗前后6个月阿片类药物使用情况。结果显示GNRFA总体安全性与关节腔内注射相似,但30天肿胀率显著高于CSI(9.4% vs 6.4%,p=0.003);无既往阿片使用患者消融后30天阿片用量显著增加,而有既往使用患者6个月阿片用量在各组均普遍下降。
要点
- GNRFA的30天和90天严重并发症率与关节腔内注射相似,但30天肿胀率显著高于CSI。
- 无既往阿片使用的患者接受GNRFA后30天内阿片类药物用量显著增加。
- 有既往阿片使用的患者,GNRFA与关节腔内注射在6个月时均见阿片用量普遍下降。
核心结论
- GNRFA安全性特征与关节腔内注射相似,但静脉血栓栓塞症和化脓性关节炎等严重不良事件可能罕见发生。
- 与关节腔内注射相比,GNRFA后30天内阿片类药物使用总体增加,但有既往阿片使用患者6个月时阿片消耗降低程度与对照组相似。
研究设计与样本
- 匹配队列研究,查询大型国家数据库识别2015至2022年接受GNRFA的患者,并匹配接受膝关节腔内皮质类固醇注射(CSI)或透明质酸注射(HAI)的对照组。
- 分析治疗后30天和90天的并发症率,并评估治疗前6个月和治疗后6个月的阿片类药物使用情况。
主要发现
- 30天时,GNRFA组肿胀率显著高于CSI组(9.4%,CI 7.6% to 10.4% vs 6.4%,CI 4.8% to 7.2%,p=0.003)。
- 30天时,感染、化脓性关节炎、深静脉血栓、肺栓塞、出血、血清肿、神经损伤和热损伤率在GNRFA与CSI组间无显著差异。
- 90天时,化脓性关节炎、深静脉血栓、肺栓塞和神经损伤率在GNRFA与CSI组间无显著差异。
- 30天和90天时,GNRFA与HAI组间感染、化脓性关节炎、深静脉血栓、肺栓塞、出血、血清肿、神经损伤、肿胀和热损伤率均无显著差异。
- 治疗前阿片使用水平无显著差异,但GNRFA组总体平均每日吗啡当量消耗更高;无既往阿片使用患者消融后30天阿片使用显著增加。
关键数值与推荐
- 30天肿胀率:GNRFA组9.4%(CI 7.6% to 10.4%)vs CSI组6.4%(CI 4.8% to 7.2%),p=0.003。
- 30天感染率:GNRFA组0.1%(CI 0.02% to 0.5%)vs CSI组0.2%(CI 0.05% to 0.6%),无显著差异。
- 30天深静脉血栓率:GNRFA组2.0%(CI 1.3% to 2.7%)vs CSI组1.6%(CI 1.0% to 2.2%),无显著差异。
- 30天肺栓塞率:GNRFA组1.2%(CI 0.6% to 1.7%)vs CSI组1.3%(CI 1.1% to 2.5%),无显著差异。
- 90天神经损伤率:GNRFA组0%(CI 0% to 0.3%)vs CSI组0%(CI 0% to 0.3%),无显著差异。
临床怎么用
- GNRFA可用于严重膝骨关节炎疼痛,但需告知患者术后30天肿胀风险略高于皮质类固醇注射。
- 对无既往阿片使用的患者,GNRFA后30天内应关注阿片类药物使用可能增加。
- 有既往阿片使用患者,GNRFA与关节腔内注射在6个月时均可能降低阿片消耗,无明确最优选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Genicular nerve radiofrequency ablation (GNRFA) is an emerging procedure used to relieve pain from severe knee osteoarthritis. While there have been rare reports of significant complications, their incidence has not been well established. The objective of this study was to examine complication rates at 30 and 90 days post treatment as well as characterize opioid-prescribing patterns before and after treatment. METHODS: A large national database was queried to identify patients undergoing GNRFA from 2015 to 2022 and matched to control cohorts composed of patients receiving either intra-articular corticosteroid (CSI) or hyaluronic acid injection (HAI) of the knee. Complication rates at 30 and 90 days were analyzed. Opioid utilization was assessed in the 6 months before and after treatment. RESULTS: Rates of infection (0.1%, CI 0.02% to 0.5% vs 0.2%, CI 0.05% to 0.6%), septic arthritis (<0.1%, CI 0.003% to 0.4% vs 0.1%, CI 0.02% to 0.5%), deep vein thrombosis (2.0%, CI 1.3% to 2.7% vs 1.6%, CI 1.0% to 2.2%), pulmonary embolism (1.2%, CI 0.6% to 1.7% vs 1.3%, CI 1.1% to 2.5%), bleeding (<0.1%, CI 0.003% to 0.4% vs 0%, CI 0% to 0.3%), seroma (<0.1%, CI 0.003% to 0.4% vs 0.2%, CI 0.05% to 0.6%), nerve injury (0%, CI 0% to 0.3% vs 0%, CI 0% to 0.3%) and thermal injury (0%, CI 0% to 0.3% vs 0%, CI 0% to 0.3%) were not different between CSI and GNRFA cohorts at 30 days. Rate of swelling was significantly greater in the GNRFA cohort (9.4%, CI 7.6% to 10.4% vs 6.4%, CI 4.8% to 7.2%, p=0.003) at 30 days. At 90 days, rates of septic arthritis (0.1%, CI 0.02% to 0.5% vs 0.3%, CI 0.08% to 0.7%), deep vein thrombosis (3.1%, CI 2.1% to 3.8% vs 3.1%, CI 2.2% to 3.9%), pulmonary embolism (1.5%, CI 0.9% to 2.1% vs 1.8%, CI 1.2% to 2.5%), and nerve injury (0%, CI 0% to 0.3% vs <0.1%, CI 0.003% to 0.4%) were not significantly different.Between HAI versus GNRFA cohorts, no significant differences were seen in rates of infection (0.3%, CI 0.08% to 0.07% vs 0.7%, CI 0.3% to 1.2%), septic arthritis (0.2%, CI 0.05% to 0.6% vs 0.4%, CI 0.2% to 0.9%), deep vein thrombosis (2.0%, CI 1.3% to 2.7% vs 1.9%, CI 1.2% to 2.7%), pulmonary embolism (1.5%, CI 0.9% to 2.2% vs 1.7%, CI 1.1% to 2.5%), bleeding (0.1%, CI 0.02% to 0.5% vs 0.2%, CI 0.05% to 0.6%), seroma (<0.1%, CI 0.03% to 0.4% vs 0%, CI 0% to 0.3%), nerve injury (0%, CI 0% to 0.3% vs 0%, CI 0% to 0.3%), swelling (14.0%, CI 11.6% to 15.1% vs 12.0%, CI 10.3% to 13.6%), and thermal injury (<0.1%, CI 0.03% to 0.4% vs <0.01%, CI 0.3% to 0.4%) at 30 days. Rates of infection (0.7%, CI 0.3% to 1.2% vs 1.4%, CI 0.9% to 2.1%), septic arthritis (0.3%, CI 0.1% to 0.8% vs 0.5%, CI 0.2% to 1.1%), deep vein thrombosis (3.6%, CI 2.6% to 4.4% vs 3.1%, CI 2.2% to 4.0%), pulmonary embolism (2.3%, CI 1.5% to 3.0% vs 2.1%, CI 1.4% to 3.0%) and nerve injury (0%, CI 0% to 0.3% vs 0.1%, CI 0.02% to 0.5%) were not significantly different at 90 days.There were no significant differences in level of pretreatment opioid utilization although overall consumption in mean daily morphine equivalents was greater in the GNRFA cohort. Opioid utilization significantly increased in the first 30 days after ablation in patients with no prior opioid use compared to controls. In patients with some and chronic prior opioid use, opioid requirements were generally decreased in all treatment groups at 6 months with no clearly superior treatment in reducing opioid consumption. CONCLUSION: Our study demonstrated that GNRFA possesses a safety profile similar to that of intra-articular injections although significant adverse events such as venous thromboembolism and septic arthritis may occur rarely. Although opioid utilization generally increased in the 30 days after ablation compared with intra-articular injection, similar reduction in opioid consumption at 6 months was seen in patients with prior opioid use in the ablation and control cohorts.
引用
- Fuqua A, Premkumar A, Jayaram P, et al. Complications and opioid-prescribing patterns following genicular nerve radiofrequency ablation versus intra-articular injection: a matched cohort study. Reg Anesth Pain Med. 2025. PMID: 38302251. doi:10.1136/rapm-2023-105053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。